Co-Founder and Chief Executive of Cell Therapy Ltd - the innovative regenerative medicine company that he founded with Nobel Laureate, Professor Martin Evans.
Cell Therapy invents and develops Regenerative Medicines for Life™ - breakthrough cellular medicines that treat life threatening / life changing diseases. In 2014, Cell Therapy completed Phase II clinical trials in End-stage heart failure with Phase III trials starting in 2015. The company’s pipeline also includes consists of 2 more disease specific products in Phase II trials for Orthopaedic and Dermatology indications.
Ajan is an inventor of CTL’s core technology and tissue specific regenerative medicine products and leads the company’s commercial and operational activities.
Ajan was Roche’s Global Head of Emerging Technologies overseeing the identification, acquisition and development of the next generation of breakthrough Biopharma technologies and products. He joined Roche as Business Development Director in Roche Pharma, where he led M&A teams and major licensing transactions including the $1.3B licensing transaction with Alnylam.
Prior to Roche, Ajan was a consultant with the Boston Consulting Group and received a MBA from Kellogg Business School, Northwestern University where he was awarded the Biotechnology scholarship. In 2002, he was awarded the UK Fulbright Scholarship.